Delcath Systems to Present at Two Key Investor Conferences in September 2026
Event summary
- Delcath Systems will present at the Wells Fargo Healthcare Conference on September 10, 2026, in Boston.
- The company will also participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 15, 2026, in New York.
- Delcath focuses on interventional oncology, specifically treating primary and metastatic liver cancers.
- The company's key products include HEPZATO KIT and CHEMOSAT Hepatic Delivery System for Melphalan.
The big picture
Delcath Systems' participation in these investor conferences comes at a critical time as the company seeks to expand its market presence in interventional oncology. The strategic focus on liver cancer treatments aligns with growing demand for targeted therapies in oncology. The company's ability to secure and maintain regulatory approvals will be key to its long-term success.
What we're watching
- Investor Sentiment
- How Delcath's presentations will impact investor confidence and stock performance.
- Regulatory Dynamics
- Whether the company can sustain its regulatory approvals and expand market reach.
- Commercialization Pace
- The pace at which Delcath can commercialize its products and penetrate the liver cancer treatment market.
Related topics